Just months after striking its $11.5 billion deal for Acceleron Pharma, Merck & Co. has telegraphed its plans to cut back at its newly acquired unit. Merck is laying off a clutch of Acceleron staffers ...

Merck, one of the premier leaders in research-intensive biopharmaceuticals, is recognized on a global scale for its development of medicine and vaccines, including vaccines for human papillomavirus ...